Trophos initiates pivotal efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease)

Trophos, a pharmaceutical company focused on underserved conditions in neurology and cardiology, is beginning a study of the efficacy of their drug olesoxime after phase I trials revealed the drug to be safe and well-tolerated. The trial is expected to take 18 months and Trophos is planning to recruit 500 ALS patients.

Click here to read this article.

Share this: